Clinical trials: Inflammation Chronic
Mild Gastrointestinal Symptoms in Healthy Adults, Low-grade Chronic Inflammation
Fungal Fiber for Gut Health
This study compares effects of plant based fiber vs fungi based fiber on clinical outcomes related to gut function (immunity, emotions, stress) and explores the role of gut microbiome structure and function on individual…
- Conditions
- Mild Gastrointestinal Symptoms in Healthy Adults, Low-grade Chronic Inflammation, Stress, Gut Health
- Trial name
- FUN4GUT (NCT06404749)
- Testing
- fungal fiber, inulin
- Where
- Argentina
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Future Biome SA
ESRD
Influence of the PEPA Membrane on the Undernutrition Syndrome Inflammation in Chronic Hemodialysis
NutriPEPA2 is a randomized, single-blind, prospective, multicenter trial, in two parallel arms to confirm that the adsorbent PEPA membrane may decrease mortality related to inflammation and malnutrition encountered in HD or…
- Trial name
- NutriPEPA2 (NCT04185571)
- Testing
- PEPA
- Where
- 12 sites in France, Monaco
- Volunteers
- 106 people
- Sponsor
- Theradial
Staphylococcus Aureus
A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)
The purpose of this study is to evaluate the safety and pharmacokinetics (PK) of AZD7760 when given as an intravenous infusion to healthy participants (Phase I) or participants with end-stage kidney disease receiving hemodialysis…
- Trial name
- PEAK (NCT06749457)
- Testing
- AZD7760
- Where
- 40 sites in United States
- Volunteers
- 242 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Osteoporosis
1 Year Open-label Extension to CZOL446H2337 Safety and Efficacy Trial of Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids
This 1-year open-label extension to CZOL446H2337 is designed to evaluate the safety and efficacy of zoledronic acid twice yearly in osteoporotic children treated with glucocorticoids.
- Trial name
- NCT01197300
- Testing
- Zoledronic acid
- Where
- 10 sites in Australia, Canada and 4 more
- Volunteers
- 25 people
- Sponsor
- Novartis Pharmaceuticals
Cigarette Smoking
Development of Biomarkers of Effect From Chronic Tobacco Usage
This study was conducted to develop biomarkers of tobacco effect that would indicate potential harm related to tobacco consumption.
- Trial name
- NCT01923402
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- R.J. Reynolds Tobacco Company
Chronic Obstructive Pulmonary Disease (COPD)
PRA-216 COPD Safety and Biomarker Study
This study will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of PRA-216 compared to placebo in patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT07730281
- Testing
- PRA-216
- Where
- 5 sites in Australia
- Volunteers
- 40 people
- Sponsor
- Prana Therapies Inc
Systemic Juvenile Idiopathic Arthritis, Hereditary Periodic Fevers
A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies
The objective of this extension protocol is to collect safety data (serious and non-serious adverse events) and to provide continuous canakinumab to patients in France who completed study CACZ885G2301E1(NCT00891046), CACZ885G2306…
- Trial name
- NCT02334748
- Testing
- canakinumab
- Where
- 3 sites in France
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
B Cell Lymphoma, NHL, Adult
SynKIR-310 for Relapsed/Refractory B-NHL
This first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administered to participants with relapsed/refractory B-NHL.
- Conditions
- B Cell Lymphoma, NHL, Adult, Mantle Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma
- Trial name
- NCT06544265
- Testing
- SynKIR-310
- Where
- 5 sites in United States
- Volunteers
- 36 people
- Sponsor
- Verismo Therapeutics
Inflammation
Effects of Transvenous Vagus Nerve Stimulation on Immune Response: a Pilot Study
The purpose of this study is to assess the effect of transvenous vagus nerve stimulation (tVNS) on the immune response. In the human endotoxemia model, intravenously administered endotoxin (lipopolysaccharide [LPS]) elicits a…
- Trial name
- NoSIRS (NCT01944228)
- Testing
- Vagal Nerve Stimulation
- Where
- Netherlands
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Asthma Acute, COPD Exacerbation Acute
Rademikibart IV for Acute Asthma and COPD Exacerbation
A Phase 2, open-label, single-arm trial to evaluate IV rademikibart as an add-on treatment for acute exacerbation in participants with asthma or COPD with type 2 inflammation
- Trial name
- NCT07705737
- Testing
- Rademikibart
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Connect Biopharm LLC
Pulmonary Disease, Chronic Obstructive
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
Depemokimab is being developed as a treatment for individuals with moderate to severe Chronic Obstructive Pulmonary Disorder (COPD).
- Trial name
- VIGILANT (NCT07177339)
- Testing
- Depemokimab
- Where
- 121 sites in United States, Australia and 11 more
- Volunteers
- 1,196 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease, COPD
A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251
To evaluate the efficacy, safety and tolerability of multiple doses of QBW251 vs placebo administered orally, on airway function, lung volume, and quality of life in patients with chronic obstructive pulmonary disease (COPD)
- Trial name
- NCT02449018
- Testing
- QBW251
- Where
- 16 sites in United States, Poland
- Volunteers
- 92 people
- Sponsor
- Novartis Pharmaceuticals
Sarcopenia, Frailty
Evaluation of Efficacy, Tolerability, and Pharmacokinetics of MYMD1 for Chronic Inflammation and Sarcopenia/Frailty
The study will be conducted to investigate the efficacy, tolerability and pharmacokinetics of MYMD1 in participants with chronic inflammation associated with sarcopenia/frailty, a condition linked to elevated levels of…
- Conditions
- Sarcopenia, Frailty, Aging
- Trial name
- NCT05283486
- Testing
- MYMD-1 600MG, MYMD-1 750mg, MYMD-1 900mg
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- TNF Pharmaceuticals, Inc.
Non-infectious Uveitis
A Safety Study of Intravitreal PP-001 in Patients With Chronic, Non-Infectious Uveitis
In this study, PP-001 is assessed for safety and efficacy in patients diagnosed with non-infectious chronic uveitis. PP-001 is a novel small molecule that inhibits a specific enzyme (Dihydroorotate Dehydrogenase) and has shown…
- Trial name
- NCT03634475
- Testing
- PP-001
- Where
- 9 sites in Austria, Belgium and 3 more
- Volunteers
- 12 people
- Sponsor
- Panoptes Pharma GmbH
Chronic Inflammation, Mobility
Effect of Maolactin™ FMR on Exercise Recovery, Inflammation and Muscle Comfort in an Otherwise Healthy Population
This is a double blind, randomised, placebo-controlled, parallel-group trial to evaluate the effect of Maolactin FMR supplementation on chronic inflammation, mobility and muscle and joint pain in an otherwise healthy population…
- Conditions
- Chronic Inflammation, Mobility, Muscle Pain, Joint Pain
- Trial name
- NCT06444763
- Testing
- Maolactin, Maltodextrin
- Where
- Australia
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- RDC Clinical Pty Ltd
Chronic Heart Failure
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure
The primary objective of this study is to determine whether transendocardial delivery of allogeneic human bone marrow-derived mesenchymal precursor cells (MPCs [rexlemestrocel-L]) is effective in the treatment of chronic heart…
- Trial name
- DREAM HF-1 (NCT02032004)
- Testing
- Rexlemestrocel-L
- Where
- 59 sites in United States, Canada
- Volunteers
- 565 people
- Sponsor
- Mesoblast, Inc.
End Stage Renal Disease, Inflammation
Permeability Enhancement to Reduce Chronic Inflammation
Chronic dialysis patients with end stage renal disease have an increased mortality rate as compared to the age matched healthy population.
- Trial name
- PERCI (NCT01582893)
- Testing
- HCO1100, P210H
- Where
- 2 sites in Germany
- Volunteers
- 50 people
- Sponsor
- Vantive Health LLC
Asthma, COPD
The Effect of FP-025, on Allergen-induced Airway Responses in Mild Eosinophilic House Dust Mite (HDM)-Allergic Asthma.
This study is a Phase IIa, randomized, placebo-controlled, double-blind, 2-way crossover, 2-center (conducted in EU; The Netherlands) study in male and female subjects with stable, mild HDM-allergic asthma.
- Trial name
- NCT03858686
- Testing
- FP-025 capsules
- Where
- 2 sites in Netherlands
- Volunteers
- 27 people
- Sponsor
- Foresee Pharmaceuticals Co., Ltd.
Kidney Failure
Effect of Paricalcitol on Markers of Inflammation in Hemodialysis Patients
Studies have shown that patients with ESRD on hemodialysis have high levels of inflammatory markers which may contribute to the high rates of cardiovascular disease and mortality seen in these patients.
- Trial name
- NCT00294866
- Testing
- Paricalcitol
- Where
- 6 sites in United States
- Volunteers
- 64 people
- Sponsor
- Fresenius Medical Care North America
Non-cystic Fibrosis Bronchiectasis
Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB)
This study is a proof-of-concept phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose selection study designed to explore the efficacy, safety, and tolerability of 2 active treatment regimens…
- Trial name
- NCT07048262
- Testing
- CSL787, Nebulizer
- Where
- 13 sites in Australia, Japan
- Volunteers
- 180 people
- Sponsor
- CSL Behring